,0
symbol,NGM
price,19.5
beta,0.0
volAvg,159687
mktCap,1342142080
lastDiv,0.0
range,9.245-23.95
changes,0.43
companyName,NGM Biopharmaceuticals Inc
currency,USD
cik,0001426332
isin,US62921N1054
cusip,62921N105
exchange,NasdaqGS
exchangeShortName,NASDAQ
industry,Biotechnology
website,https://www.ngmbio.com/
description,"NGM Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company is headquartered in South San Francisco, California and currently employs 164 full-time employees. The Companyâ€™s product candidates include NGM282, NGM313, NGM386, NGM395, NGM120, NGM217 and NGM621. NGM282 is an engineered variant of the human hormone known as FGF19, which the Company is developing for the treatment of non-alcoholic steatohepatitis (NASH). NGM313 is an agonistic antibody selectively activating fibroblast growth factor receptor 1c-beta-klotho and has the potential as an insulin sensitizer for the treatment of type two diabetes and NASH. NGM386 and NGM395 are engineered variants of the human hormone known as GDF15, which is developed for the treatment of obesity. NGM120 is an antagonistic antibody binding glial cell-derived neurotrophic factor receptor alpha-like, or GFRAL, that is designed to inhibit the effects of elevated GDF15 levels on cancer anorexia/cachexia syndrome, and cancer."
ceo,Mr. David Woodhouse
sector,Healthcare
country,US
fullTimeEmployees,186
phone,16502435555
address,333 Oyster Point Blvd
city,South San Francisco
state,CALIFORNIA
zip,94080
dcfDiff,
dcf,21.4629
image,https://financialmodelingprep.com/image-stock/NGM.png
ipoDate,2019-04-04
defaultImage,False
